Asian Pacific Journal of Tropical Medicine (Jan 2018)

Efficacy of voriconazole on leishmaniasis by Leishmania major: An in vitro and in vivo study

  • Ahmad Oryan,
  • Somayeh Bahrami,
  • Effat Bemani

DOI
https://doi.org/10.4103/1995-7645.244516
Journal volume & issue
Vol. 11, no. 10
pp. 562 – 569

Abstract

Read online

Objective: To appraise the activity of voriconazole against Leishmania major (L. major) in vitro and its effectiveness on wound regeneration in cutaneous leishmaniasis in BALB/c mice. Methods: The IC50 of voriconazole against promastigotes and intra-macrophage amastigotes of L. major was investigated in vitro. The in vivo study was performed by treating the L. major infected BALB/c mice. When the wounds appeared in the base of tail, treatment was started by administration of 30 mg/kg voriconazole for 28 consecutive days orally. Results: The IC50 of voriconazole against promastigotes and intra-macrophage amastigotes were 0.74 and 0.89 ģĢ, respectively. Voriconazole decreased lipid peroxidation and IL-6 level. Histopathological findings indicated accelerated healing in the voriconazole treated group compared to other groups. Conclusions: Our results demonstrate that voriconazole can be an option in treating the cutaneous leishmaniasis by L. major.

Keywords